Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)
This is an investigator-initiated, single-center clinical trial evaluating the efficacy and safety of ALK inhibitors in patients with locally advanced or metastatic bone cancer harboring truncated ALK (ALKATI) alterations. Eligible patients must have disease progression after standard therapy or no suitable standard treatment options.
Participants will receive either crizotinib (Xalkori®) or alectinib (Alecensa®), with treatment selection determined by the study investigators. The study aims to assess antitumor activity, safety, and clinical outcomes in this rare molecular subtype of bone cancer.
연구 개요
상세 설명
This is an investigator-initiated, single-center clinical trial evaluating the safety and efficacy of ALK inhibitors in patients with locally advanced or metastatic bone cancer harboring truncated ALK (ALKATI) alterations. This molecular subtype has been associated with poor prognosis and limited response to conventional therapies.
Preclinical studies conducted by the study team have demonstrated that ALK inhibitors, including crizotinib (Xalkori®) and alectinib (Alecensa®), exhibit antitumor activity against bone cancer cells with truncated ALK expression. Based on these findings, this study aims to explore their therapeutic potential in a clinical setting.
Eligible patients are those who have experienced disease progression after standard treatment or have no appropriate standard treatment options available. Participants will receive oral ALK inhibitor therapy, with treatment selection and dose adjustments determined by the investigators based on clinical response and tolerability.
The primary objective of this study is to evaluate antitumor activity in this rare molecular subset of bone cancer. Secondary objectives include safety, tolerability, and clinical outcomes.
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Yi-Chin Fong
- 전화번호: +886-909-183-619
- 이메일: yichin.fong@gmail.com
연구 장소
-
-
-
Taichung, 대만
- China Medical University Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Age ≥ 20 years.
- Patients with locally advanced or metastatic solid tumors harboring deficiency or alteration of anaplastic lymphoma kinase (ALK) tyrosine kinase.
- Disease progression during or within 6 months after completion of standard therapy, or no appropriate standard treatment available.
- At least one measurable lesion according to applicable response evaluation criteria.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Estimated life expectancy of at least 8 weeks.
Exclusion Criteria:
- Known hypersensitivity to crizotinib or alectinib.
- Current or prior use of ALK inhibitors.
- Current use of tyrosine kinase inhibitors.
- Receipt of radiotherapy within 2 weeks prior to study entry. Palliative radiotherapy to non-target lesions is permitted.
- History of other malignancies, except for osteosarcoma or chondrosarcoma, unless the patient has been disease-free for at least 2 years. Exceptions include adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
- Liver cirrhosis with a Child-Pugh score ≥ 8.
- Uncorrectable electrolyte abnormalities.
- Presence of brain metastases.
- Active acute infection.
- Significant unresolved toxicity from prior therapy.
- Comorbid conditions that may interfere with study participation, including but not limited to uncontrolled diabetes mellitus, autoimmune diseases, or any condition that, in the investigator's judgment, renders the patient unsuitable for the study.
- Concurrent malignancy, unless it is adequately treated carcinoma in situ or basal cell carcinoma, or a malignancy that has been treated and has remained recurrence-free for at least 3 years.
- Pregnant or breastfeeding women.
- Patients with psychiatric disorders that may impair compliance with study requirements.
- Current use of strong inducers or inhibitors of CYP3A enzymes, or use of other investigational or non-approved drugs.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: ALK Inhibitor Treatment
Alectinib: 450 mg/day, administered orally, three times daily (one capsule per dose).
|
Patients will receive oral anaplastic lymphoma kinase (ALK) inhibitor therapy for locally advanced or metastatic bone cancer harboring truncated ALK (ALKATI) alterations. Treatment will include alectinib. The dosing regimen of alectinib, including starting dose and any subsequent adjustments, will be determined by the investigators based on clinical response and tolerability. Each treatment cycle is defined as 4 weeks. Drug selection and dose modifications will be at the discretion of the investigators. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal from the study. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective Response Rate (ORR)
기간: Up to 24 weeks (or every 8-12 weeks per imaging assessment)
|
Objective response rate, defined as the proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST 1.1 criteria.
|
Up to 24 weeks (or every 8-12 weeks per imaging assessment)
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Department of Orthopedics, China Medical University Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
골암에 대한 임상 시험
-
Centre Hospitalier Régional d'Orléans완전한Bone Scintigraphy 동안 두 Collimator의 비교프랑스
-
Mansoura University모집하지 않고 적극적으로
-
Mansoura University아직 모집하지 않음회복 불가능한 구치 | 얇은 협측 골판 | Buccal Bone Fenestraion이집트
-
Azhar ALI ELSAYED SELEEM알려지지 않은Crestal Bone 흡수 | 임플란트 기본 안정성 | 임플란트 골융합
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of Salamanca완전한교정 장치 합병증 | 부정교합 | 상악 저형성증 | Bone Anchored Rapid 상악 확장 | BAME스페인
-
University of UtahNational Cancer Institute (NCI)완전한피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
SB Istanbul Education and Research Hospital아직 모집하지 않음Thryoid cancer | parathyrıoid 선종
-
Jonsson Comprehensive Cancer CenterNovartis Pharmaceuticals모병전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center모병전립선 선암종 | 2기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
Alectinib에 대한 임상 시험
-
First People's Hospital of HangzhouZhejiang University; General Hospital of Ningxia Medical University모병
-
Memorial Sloan Kettering Cancer CenterGenentech, Inc.; Secura Bio, Inc.모병
-
Cancer Research UKRoyal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University...모병조직학적 유형에 따른 신생물 | 림프종 | 림프 증식 장애 | 부위별 신생물 | 신장 세포 암종 | 암 | 역형성 대세포 림프종 | 신경 모세포종 | 악성 신생물 | 고형종양 | 혈액학적 악성종양영국
-
Hoffmann-La Roche모병ALK 융합 양성 고형 또는 CNS 종양미국, 중국, 스페인, 캐나다, 덴마크, 영국, 호주, 프랑스, 독일, 브라질, 대한민국, 이탈리아
-
Hoffmann-La Roche모집하지 않고 적극적으로NSCLC벨기에, 호주, 체코, 중국, 크로아티아, 리투아니아, 핀란드, 이스라엘, 페루, 세르비아, 불가리아, 포르투갈, 이탈리아, 오스트리아, 쿠바, 베트남, 아르헨티나, 칠레, 콜롬비아, 파나마, 루마니아, 아랍 에미리트, 우루과이, 터키 (Türkiye), 러시아 제국
-
Nuvalent Inc.모병비소세포폐암 | 역형성 림프종 키나제 양성벨기에, 미국, 스페인, 일본, 영국, 호주, 네덜란드, 프랑스, 폴란드, 태국, 이탈리아, 대만, 독일, 그리스, 말레이시아, 홍콩, 싱가포르, 덴마크, 포르투갈, 브라질, 멕시코, 헝가리, 대한민국, 아르헨티나, 체코, 스위스, 캐나다, 오스트리아, 칠레
-
Instituto Nacional de Cancerologia de Mexico모병
-
Massachusetts General HospitalGenentech, Inc.모집하지 않고 적극적으로
-
Takeda완전한ALK+ 고급 NSCLC스페인, 대만, 홍콩, 태국, 중국, 이탈리아, 미국, 멕시코, 크로아티아, 아르헨티나, 캐나다, 프랑스, 그리스, 루마니아, 스웨덴, 오스트리아, 대한민국, 칠레, 독일, 러시아 제국